R-GDP Regimen

1. R-GDP (Rituximab + Gemcitabine, Dexamethasone, Cisplatin)

• Indication:
  • Relapsed or refractory DLBCL and follicular lymphoma
  • Often used as salvage therapy or alternative to R-ICE before stem cell transplant
• Eligible Patients:
  • Transplant-eligible patients needing a salvage regimen
  • Also appropriate for older or frailer patients due to lower toxicity profile
• Pros:
  • Less intensive, outpatient-friendly
  • Reduced neurotoxicity compared to regimens with vincristine or high-dose cytarabine
  • Shorter infusion time and fewer hospital admissions
• Key Toxicities:
  • Myelosuppression (neutropenia, thrombocytopenia)
  • Nephrotoxicity (from cisplatin)
  • Nausea/vomiting (moderate emetogenic risk)
  • Fatigue, infections